Monument Therapeutics, in collaboration with the University of Nottingham, has announced a preclinical study to support the use of their non-invasive biomarker for cognitive impairment in schizophrenia. Currently, there are no treatments on the market for cognitive impairment associated with schizophrenia, despite efforts by pharmaceutical companies over… Read More
News round-up by DDW’s Megan Thomas for 13-17 September The news in the drug discovery industry this week has demonstrated the potential that remains untapped for a number of industries at large as well as taking early steps towards future cures and treatments. DDW’s Megan Thomas has… Read More
Registration for SLAS 2022 International Conference and Exhibition is available for in-person attendance in Boston or the online digital experience, with the option to change online or in-person status later. Abstract submission is still open and applicants can choose to present in-person or online. Student Poster Awards… Read More
Bristol-led research has identified specific drug targets within the neural circuits that encode memories, paving the way for significant advances in the treatment of a broad spectrum of brain disorders. Loss of memory is a core feature of many neurological and psychiatric disorders including Alzheimer’s disease and… Read More
Illumina and Merck have partnered to develop and commercialise tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD). Patients whose tumours are HRD-positive may be eligible for targeted treatment by a class of precision medicines called PARP inhibitors. The HRD tests will leverage Illumina’s TruSight Oncology 500 (TSO… Read More
Swedish company Gedea Biotech has announced that it has enrolled more than 50% of patients in the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The randomised double-blind placebo-controlled study is designed to confirm the safety and efficacy of pHyph and is coordinated by Nottingham University… Read More
New analysis suggests that the Moderna Covid-19 vaccine is highly effective against circulating variants of concern, including in a vaccine effectiveness study conducted in partnership with Kaiser Permanente Southern California (KPSC) and in a separate recent publication by the US Centers for Disease Control and Prevention (CDC). Additionally, the company shared… Read More
If you are interested in understanding how to optimise analytical methods to accelerate biosimilar development, watch this exclusive DDW event, supported by Bio-Techne. Using an automated CE-SDS platform in efficient biosimilar comparability studies, which took place on 29 September at 4PM BST. Watch on Demand… Read More
GlobalData has predicted that the arrival of biosimilar therapies in the EU will continue to fall in the coming years following a wave pattern that has been occurring since 2006. GlobalData’s senior drugs database analyst Quentin Horgan notes that we are currently in the downward trajectory of a wave that peaked in… Read More
Benchling, the biotechnology cloud R&D platform used by organisations including Regeneron, Gilead and Pfizer, hosted a virtual event on September 14 at 8 am PT / 11 am ET called Drive Innovation from Discovery to Development, where the company announced its entry into the Early Development market, launching new solutions that… Read More
Pharming Group has announced the topline results from two randomised, open label, controlled, pilot clinical trials of patients hospitalised with Covid-19 treated with Ruconest (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infection. The primary endpoint in both studies was disease severity on the seven-point WHO ordinal scale on Day Seven. … Read More
Hutchmed has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) for amdizalisib (HMPL-689), a highly selective and potent PI3Kδ inhibitor, for the treatment of relapsed or refractory follicular lymphoma (FL), a subtype of non-Hodgkin’s lymphoma (NHL). Drug candidates with… Read More
Nottingham, UK-based contract research organisation (CRO) Cellomatics Biosciences has reported year-on-year organic revenue growth of 30% since its inception in 2015, as demand for its preclinical and early discovery phase laboratory services and expertise continues to increase. Based at BioCity Nottingham, Cellomatics is a specialist preclinical CRO with expertise in five main therapeutic areas: oncology,… Read More
Beckley Psytech has dosed the first patient in a world-first clinical trial exploring the effects of psilocybin for treating Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The outcome of the Phase Ib study, with proof-of-concept efficacy data, is expected to be available in early 2022. The clinical trial is being… Read More
Vaccination is the most effective method of preventing infectious diseases, and is considered one of the greatest achievements in medicine. This brochure, released by Sartorius, is designed to demonstrate precision and safety at its finest. Until today, various vaccines against several crucial diseases (including influenza,… Read More
Enterprise Lithuania and the Lithuanian Biotechnology Association has announced that in 2020, the Lithuanian biotechnology sector grew by a record 87% and accounted for 2.5% of the Baltic nation’s GDP. Industry leaders gathering at the upcoming Life Sciences Baltics forum are now calling for more international collaborations, increased investment and… Read More
